177Lu Video indir

How To Administer The Investigational Radiopharmaceutical 177Lu-Psma-It
3:30
7.544
Science Animated
How To Administer The Investigational Radiopharmaceutical 177Lu-Psma-It
2 yıl önce
177Lu-Psma-617 For The Early Treatment Of Prostate Cancer
5:37
1.774
VJOncology
177Lu-Psma-617 For The Early Treatment Of Prostate Cancer
4 yıl önce
177Lu-Psma-617 For Prostate Cancer Therap, Vision, Upfrontpsma And Lutectomy
6:45
1.979
VJOncology
177Lu-Psma-617 For Prostate Cancer Therap, Vision, Upfrontpsma And Lutectomy
4 yıl önce
Dr. Chauhan On The Role Of 177Lu-Dotatate In Nets
1:47
843
OncLive
Dr. Chauhan On The Role Of 177Lu-Dotatate In Nets
5 yıl önce
Asco24 Updates Innovative 177Lu-Psma-617 Therapy Enhanced Survival In Prostate Cancer
2:59
211
OncoDaily TV
Asco24 Updates Innovative 177Lu-Psma-617 Therapy Enhanced Survival In Prostate...
1 yıl önce
177Lu-Psma-617 Radionuclide Therapy In Mcrpc
5:27
2.616
VJOncology
177Lu-Psma-617 Radionuclide Therapy In Mcrpc
6 yıl önce
Production Of N.c.a. Lutetium-177 Endolucinbeta For Targeted Radionuclide Therapy
2:46
8.033
ITM Isotope Technologies Munich SE
Production Of N.c.a. Lutetium-177 Endolucinbeta For Targeted Radionuclide...
7 yıl önce
Safety And Efficacy Of 177Lu-Psma-617
3:17
1.057
GU Oncology Now
Safety And Efficacy Of 177Lu-Psma-617
2 yıl önce
177Lu-Dotatate In Patients With Well-Differentiated, High-Grade Nets
1:57
550
VJOncology
177Lu-Dotatate In Patients With Well-Differentiated, High-Grade Nets
3 yıl önce
The Benefits Of 177Lu-Psma-617 Plus Olaparib For Prostate Cancer
1:06
320
VJOncology
The Benefits Of 177Lu-Psma-617 Plus Olaparib For Prostate Cancer
2 yıl önce
177Lu-Psma-617 For Metastatic Castration-Resistant Prostate Cancer
0:28
653
VJOncology
177Lu-Psma-617 For Metastatic Castration-Resistant Prostate Cancer
3 yıl önce
Vision Secondary Analysis Of 177Lu-Psma-617 And Arpis In Mcrpc
2:25
163
VJOncology
Vision Secondary Analysis Of 177Lu-Psma-617 And Arpis In Mcrpc
10 ay önce
Starlite-1 177Lu-Girentuximab, Cabozantinib Nivolumab In Ccrcc
0:54
63
VJOncology
Starlite-1 177Lu-Girentuximab, Cabozantinib Nivolumab In Ccrcc
6 ay önce
Dr. Strosberg On Future Of 177Lu-Dotatate Therapy In Neuroendocrine Tumors
1:19
1.417
OncLive
Dr. Strosberg On Future Of 177Lu-Dotatate Therapy In Neuroendocrine Tumors
8 yıl önce
Vision Tolerability Of 177Lu-Psma-617 By Treatment Exposure In Patients With Mcrpc
3:03
796
VJOncology
Vision Tolerability Of 177Lu-Psma-617 By Treatment Exposure In Patients With...
3 yıl önce
Snmmi 2024 Dosimetry Of 177Lu-Psma Rlts, Flex-Mrt, And More
6:23
112
GU Oncology Now
Snmmi 2024 Dosimetry Of 177Lu-Psma Rlts, Flex-Mrt, And More
1 yıl önce
Upfront 177Lulu-Psma-617 Radioligand Therapy Prior To Radical Prostatectomy In Men With Hr Pc
4:28
566
ecancer
Upfront 177Lulu-Psma-617 Radioligand Therapy Prior To Radical Prostatectomy In...
2 yıl önce
Renalut 177Lu-Psma-617 In Metastatic Pre-Treated Ccrcc
3:52
54
VJOncology
Renalut 177Lu-Psma-617 In Metastatic Pre-Treated Ccrcc
2 ay önce
177Lu-Dotatate Improves Outcomes In Advanced Gep-Nets Versus Octreotide
2:05
19
VJOncology
177Lu-Dotatate Improves Outcomes In Advanced Gep-Nets Versus Octreotide
5 gün önce
Fractionated Dose 177Lu-Psma-617 In Patients With Mcrpc
5:30
273
VJOncology
Fractionated Dose 177Lu-Psma-617 In Patients With Mcrpc
4 yıl önce
Phase 3 Trial Of 177Lu-Dotatate For Midgut Neuroendocrine Tumors
5:53
1.059
The Healthcare Channel
Phase 3 Trial Of 177Lu-Dotatate For Midgut Neuroendocrine Tumors
8 yıl önce
Pro-Xl Evaluating Zanzalintinib In Mcrpc After 177Lu-Psma-617 Progression
0:48
128
VJOncology
Pro-Xl Evaluating Zanzalintinib In Mcrpc After 177Lu-Psma-617 Progression
10 ay önce
Therap Cabazitaxel Versus 177Lu-Psma-617 For Mcrpc
2:37
394
VJOncology
Therap Cabazitaxel Versus 177Lu-Psma-617 For Mcrpc
4 yıl önce
Efficacy And Toxicity Of 177Lu-Psma-617 For Mcrpc In A Real-World Setting
5:45
193
GU Oncology Now
Efficacy And Toxicity Of 177Lu-Psma-617 For Mcrpc In A Real-World Setting
1 yıl önce
Netter-1 Update 177Lu-Dotatate In Patients With Midgut Neuroendocrine Tumors
1:59
570
VJOncology
Netter-1 Update 177Lu-Dotatate In Patients With Midgut Neuroendocrine Tumors
4 yıl önce
Lu 177 Psma Therapy For Prostate Cancers
2:36
3.414
Narvesh Kumar
Lu 177 Psma Therapy For Prostate Cancers
3 yıl önce
Lutetium-177 Psma Guided Treatment
11:01
21.579
Prostate Cancer Research Institute
Lutetium-177 Psma Guided Treatment
3 yıl önce
Preserve-006 Gotistobart And 177Lu-Psma-617 In Pre-Treated Mcrpc
1:51
84
VJOncology
Preserve-006 Gotistobart And 177Lu-Psma-617 In Pre-Treated Mcrpc
6 ay önce
Insights Into Real-World Use Of 177Lu-Psma-617 In Patients With Mcrpc
1:26
96
VJOncology
Insights Into Real-World Use Of 177Lu-Psma-617 In Patients With Mcrpc
10 ay önce
Vision Safety Analysis Of 177Lu-Psma-617 In Mcrpc
1:35
52
VJOncology
Vision Safety Analysis Of 177Lu-Psma-617 In Mcrpc
1 yıl önce
Psmaddition 177Lu-Psma-617 Plus Adt And Arpi In Psma-Positive Mhspc
2:08
93
VJOncology
Psmaddition 177Lu-Psma-617 Plus Adt And Arpi In Psma-Positive Mhspc
2 ay önce
177Lu-Psma It For Patients With Psma-Positive Mcrpc
1:38
108
VJOncology
177Lu-Psma It For Patients With Psma-Positive Mcrpc
3 yıl önce
Dr. Gafita On Prognostic Models For Treatment With 177Lu-Psma-617 In Mcrpc
1:02
185
OncLive
Dr. Gafita On Prognostic Models For Treatment With 177Lu-Psma-617 In Mcrpc
5 yıl önce
Expert Discusses Fractionated Dose 177Lu-Psma-617 In Mcrpc
1:48
398
Targeted Oncology
Expert Discusses Fractionated Dose 177Lu-Psma-617 In Mcrpc
7 yıl önce
Dr. Strosberg On Retreatment With 177Lu-Dotatate In Advanced Nets
1:03
391
OncLive
Dr. Strosberg On Retreatment With 177Lu-Dotatate In Advanced Nets
5 yıl önce
The Development And Results Of A Dose-Intense Regimen Using 177Lu-Psma-617 For Progressive Mcrpc
2:02
82
VJOncology
The Development And Results Of A Dose-Intense Regimen Using 177Lu-Psma-617 For...
1 yıl önce
Lunar A Randomised Phase 2 Study Of 177Lu-Psma Neoadjuvant To Ablative Radiotherapy For Pca
3:39
210
BJUI
Lunar A Randomised Phase 2 Study Of 177Lu-Psma Neoadjuvant To Ablative...
2 yıl önce
© 2026 VideoindirXa.Net by NEMO